Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05055323 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
A Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05055323: Active Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8, sponsored by Thomas Jefferson University.
NCT05055323 is a Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8 that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 20 participants, below the 63-participant average among 16 other Stage II Pancreatic Cancer AJCC v8 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05055323, a Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable). Pyrvinium pamoate may slow down tumor growth and help patients live longer.
Primary Outcome
Considered any grade 3 or higher adverse event due to the drug itself or delay of surgery. Research coordinator will call patient every day to monitor for DLTs.
Conditions Studied
Interventions
- DRUG Pyrvinium Pamoate
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-07-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT05055323 still lists
NCT05055323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 63-participant average among 16 other Stage II Pancreatic Cancer AJCC v8 trials with a reported enrollment target (68% lower).
The record links to 8 conditions, with Stage II Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Pyrvinium Pamoate is the first listed.
NCT05055323 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05055323 about?
NCT05055323 is a clinical study titled "A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer". This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable). Pyrvinium pamoate may slow down tumor growth and help patients live longer.
What is the current status of trial NCT05055323?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-07-29. Estimated completion is 2026-12-31.
What conditions does trial NCT05055323 study?
This clinical trial studies the following conditions: Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Resectable Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8.
What interventions are being tested in trial NCT05055323?
The interventions under investigation include: Pyrvinium Pamoate (DRUG).
Who is sponsoring clinical trial NCT05055323?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05055323 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Pancreatic Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05055323's enrollment target sits among peer trials
20 13th of 16 higher than 4 of 16 other Stage II Pancreatic Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Pancreatic Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI